@paigelina's one-year Wegovy journey, fact-checked

What did @paigelina actually say?

Pretty straightforwardly, @paigelina documented a one-year journey on Wegovy (semaglutide), reporting a total weight loss of 64 pounds. She mentioned being on "the 1.7 milligram" injection, and described herself as "a slower responder on this medication." She also showed a visual before-and-after comparison using the same outfit at three points: day one, around 30 pounds lost, and at one year. No medical claims, no cure language, no dosing advice. This is a personal experience video, not a medical tutorial. She gets credit for that distinction.

The emotional framing, community connection, and self-described slower progress are worth noting because they push back against the "Ozempic before-and-after in 12 weeks" trope that dominates this corner of TikTok. That's actually a more honest representation of how this drug tends to work for many people.

Does the science back this up?

Yes, broadly. Sixty-four pounds over 12 months is within the range clinical trials have documented, though it sits toward the higher end for semaglutide specifically. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found participants lost an average of 14.9% of body weight over 68 weeks on 2.4 mg semaglutide. For a person starting at, say, 220 pounds, that would be roughly 33 pounds. Sixty-four pounds would require a starting weight closer to 430 pounds, or she had a particularly strong response.

That said, real-world outcomes vary considerably from trial averages. The STEP trials enrolled people under controlled conditions. In practice, some patients lose significantly more, some less. Her self-description as a "slower responder" is interesting given the total number, but individual response to GLP-1 agonists is genuinely variable. Rybelsus and injectable semaglutide studies consistently show a wide standard deviation in outcomes. The 64-pound figure is plausible, not extraordinary, depending on her starting weight.

What did they get wrong (or right)?

She got more right than wrong. Describing herself as a slower responder is honest and clinically consistent with real GLP-1 data. Not everyone hits double-digit percentages, and the framing of this as a gradual process counters the unrealistic "fast fix" narrative that gets a lot of people into trouble with expectations.

The one thing worth flagging: she mentions being on "the 1.7 milligram" dose. The FDA-approved Wegovy titration schedule goes 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg. So 1.7 mg is a real dose in the approved schedule, not a made-up number. She appears to still be titrating up, which means she hasn't yet reached the 2.4 mg maintenance dose. This is relevant because some patients reach their maximum weight loss before hitting the top dose, and some continue losing as they titrate. Neither scenario is wrong, but viewers should understand that "not yet at max dose" doesn't mean "not getting results."

She made no claims about curing anything, made no comparisons to compounded versions, and didn't tell anyone what dose to take. That's a better safety record than a lot of GLP-1 content on this platform.

What should you actually know?

A few things the video doesn't cover, through no fault of the creator, but worth knowing if you're considering Wegovy. First, weight loss on semaglutide tends to plateau. The STEP 5 trial (Garvey et al., 2022, Nature Medicine) showed continued benefit at two years, but the rate of loss slows considerably after the first year. What @paigelina experienced in year one may look different in year two.

Second, "skin bounced back pretty nice" is a common observation, but skin elasticity after weight loss depends heavily on age, genetics, speed of loss, and starting weight. It's not a predictable outcome. Don't plan your expectations around one person's skin response.

Third, stopping the medication typically results in weight regain. The STEP 1 extension study (Wilding et al., 2022, Diabetes, Obesity and Metabolism) found participants regained about two-thirds of their lost weight within a year of stopping semaglutide. This is a maintenance medication for most people, not a finite course. That's a conversation to have with a licensed provider, not a TikTok comment section.

• Wegovy is FDA-approved for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition.
• Individual results vary significantly from trial averages.
• The 1.7 mg dose is a real step in the approved titration schedule, not a custom dose.